MULTI 12 INJECTION 0.72 MG
VITAMIN B2 (RIBOFLAVIN-5-PHOSPHATE) : 0.72 MG VITAMIN D : 40 UNIT VITAMIN B12 (VITAMIN B12) : 1 MCG VITAMIN A : 660 UNIT VITAMIN B1 (THIAMINE HYDROCHLORIDE) : 0.6 MG BIOTIN : 12 MCG VITAMIN E : 2 UNIT FOLIC ACID : 80 MCG DEXPANTHENOL : 3 MG ASCORBIC ACID : 20 MG PYRIDOXINE HYDROCHLORIDE : 0.8 MG NICOTINAMIDE : 8 MG · DIN 02100606 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is MULTI 12 INJECTION?
MULTI 12 INJECTION 0.72 MG contains VITAMIN B2 (RIBOFLAVIN-5-PHOSPHATE) : 0.72 MG VITAMIN D : 40 UNIT VITAMIN B12 (VITAMIN B12) : 1 MCG VITAMIN A : 660 UNIT VITAMIN B1 (THIAMINE HYDROCHLORIDE) : 0.6 MG BIOTIN : 12 MCG VITAMIN E : 2 UNIT FOLIC ACID : 80 MCG DEXPANTHENOL : 3 MG ASCORBIC ACID : 20 MG PYRIDOXINE HYDROCHLORIDE : 0.8 MG NICOTINAMIDE : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02100606, held by SANDOZ CANADA INCORPORATED, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 23-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MULTI 12 INJECTION used for?
Supplement to parenteral nutrition for adults and children 11+; maintains plasma vitamin levels; prevents depletion/deficiency during stress (surgery, burns, trauma, infection, coma).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02100606 |
|---|---|
| Brand name | MULTI 12 INJECTION |
| Generic / active ingredient | VITAMIN B2 (RIBOFLAVIN-5-PHOSPHATE) : 0.72 MG VITAMIN D : 40 UNIT VITAMIN B12 (VITAMIN B12) : 1 MCG VITAMIN A : 660 UNIT VITAMIN B1 (THIAMINE HYDROCHLORIDE) : 0.6 MG BIOTIN : 12 MCG VITAMIN E : 2 UNIT FOLIC ACID : 80 MCG DEXPANTHENOL : 3 MG ASCORBIC ACID : 20 MG PYRIDOXINE HYDROCHLORIDE : 0.8 MG NICOTINAMIDE : 8 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 0.72 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XC VITAMINS |
| AHFS class | 88:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Oct-2025 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
Adults/children 11+: Add one daily dose (5 mL Vial 1 + 5 mL Vial 2) to 500-1000 mL dextrose 5% or NaCl 0.9%. Do not inject without dilution. Protect from light. Use within 24 hours.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store vials in refrigerator between 2 and 8 °C. Protect from light. Diluted solutions stable for 24 hours under refrigeration.
How is it supplied?
Boxes of 10 (5 x Vial 1 and 5 x Vial 2) in 5 mL single dose or 25 mL Pharmacy Bulk Package sizes.
Contraindications
Pre-existing hypervitaminosis; known sensitivity to any vitamins in the product. Blood sampling for megaloblastic anemia should be done before administration.
Warnings and precautions
Do not inject undiluted. Vitamin A may adhere to plastic. Fat-soluble vitamins (A, D, E) can accumulate to harmful levels. Monitor for thiamine deficiency if bisulfites are used.
What can be used instead?
Other Canadian products sharing ATC code B05XC VITAMINS. 2 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MULTI 1000 | 1.2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00586315 |
| M.V.I. 12 | 660 UNIT | LIQUID | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 01927841 |
| M.V.I. PAEDIATRIC | 1.2 MG | LIQUID | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 01927833 |
| MEGA-C-SODIUM INJ 250MG/ML | 250 MG | SOLUTION | KRIPPS PHARMACY LTD. | DORMANT | DIN 00525189 |
| MULTI-11 | 8 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02244696 |
| MULTI-12 PEDIATRIC | 1 MCG | LIQUID | SABEX INC | CANCELLED POST MARKET | DIN 02236829 |
| MULTI-VITAMINS FOR INFUSION LIQ | 200 UNIT / 10 ML | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 01904191 |
| MVC 9 PLUS 3 INJ | 15 MG / 5 ML | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01945637 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.